An overview of high-dose melphalan and stem cell transplantation in the treatment of AL amyloidosis

References

• Westermark P, Benson M D, Buxbaum J N, Cohen A S, Frangione B, Ikeda S, Masters C L, Merlini G, Saraiva M J, Sipe J D. Amyloid fibril protein nomenclature – 2002. Amyloid 2002; 9: 197–200
   PubMed Web of Science ®Google Scholar
• Gertz M A, Lacy M Q, Dispenzieri A. Amyloidosis. Hematol Oncol Clin North America 1999; 13: 1211–1220
   PubMed Web of Science ®Google Scholar
• Skinner M, Sanchorawala V, Seldin D C, Dember L M, Falk R H, Berk J L, Anderson J J, O'Hara C, Finn K T, Libbey C A, Wiesman J, Quillen K, Swan N, Wright D G. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med 2004; 140: 85–93
   PubMed Web of Science ®Google Scholar
• Kyle R A, Linos A, Beard C M, Linke R P, Gertz M A, O'Fallon W M, Kurland L T. Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. Blood 1992; 79: 1817–1822
   PubMed Web of Science ®Google Scholar
• Sanchorawala V, Wright D G, Seldin D C, Dember L M, Finn K, Falk R H, Berk J, Quillen K, Skinner M. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis. Bone Marrow Transplant 2001; 28: 637–642
   PubMed Web of Science ®Google Scholar
• Kyle R A, Gertz M A. Primary systemic amylodiosis: clinical and laboratory features in 474 cases. Semin Hematol 1995; 32: 45–49
   PubMed Web of Science ®Google Scholar
• Dember L M. Emerging treatment approaches for the systemic amyloidoses. Kidney Int 2005; 68: 1377–1390
   PubMed Web of Science ®Google Scholar
• Gertz M A, Lacy M Q, Dispenzieri A, Cheson B D, Barlogie B, Kyle R A, Palladini G, Geyer S M, Merlini G. A multicenter phase II trial of 4′-iodo-4′deoxydoxorubicin (IDOX) in primary amyloidosis (AL). Amyloid 2002; 9: 24–30
   PubMed Web of Science ®Google Scholar
• Gianni L, Bellotti V, Gianni A M, Merlini G. New drug therapy of amyloidoses: resorption of AL-type deposits with 4′-iodo-4′-deoxydoxorubicin. Blood 1995; 86: 855–861
   PubMed Web of Science ®Google Scholar
• Pepys M B, Herbert J, Hutchinson W L, Tennent G A, Lachmann H J, Gallimore J R, Lovat L B, Bartfai T, Alanine A, Hertel C, Hoffmann T, Jakob-Roetne R, Norcross R D, Kemp J A, Yamamura K, Suzuki M, Taylor G W, Murray S, Thompson D, Purvis A, Kolstoe S, Wood S P, Hawkins P N. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature 2002; 417: 254–259
   PubMed Web of Science ®Google Scholar
• Gertz M A, Comenzo R, Falk R H, Fermand J P, Hazenberg B P, Hawkins P N, Merlini G, Moreau P, Ronco P, Sanchorawala V, Sezer O, Solomon A, Grateau G. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18–22 April 2004. Am J Hematol 2005; 79: 319–328
   PubMed Web of Science ®Google Scholar
• Seldin D C, Anderson J J, Sanchorawala V, Malek K, Wright D G, Quillen K, Finn K T, Berk J L, Dember L M, Falk R H, Skinner M. Improvement in quality of life of patients with AL amyloidosis treated with high-dose melphalan and autologous stem cell transplantation. Blood 2004; 104: 1888–1893
   PubMed Web of Science ®Google Scholar
• Sanchorawala V, Seldin D C, Magnani B, Skinner M, Wright D G. Serum free light-chain responses after high-dose intravenous melphalan and autologous stem cell transplantation for AL (primary) amyloidosis. Bone Marrow Transplant 2005; 36: 597–600
   PubMed Web of Science ®Google Scholar
• Attal M, Harousseau J L, Stoppa A M, Sotto J J, Fuzibet J G, Rossi J F, Casassus P, Maisonneuve H, Facon T, Ifrah N, Payen C, Bataille R. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996; 335: 91–97
   PubMed Web of Science ®Google Scholar
• Child J A, Morgan G J, Davies F E, Owen R G, Bell S E, Hawkins K, Brown J, Drayson M T, Selby P J. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875–1883
   PubMed Web of Science ®Google Scholar
• Comenzo R L, Vosburgh E, Simms R W, Bergethon P, Sarnacki D, Finn K, Dubrey S, Faller D V, Wright D G, Falk R H, Skinner M. Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: one-year follow-up in five patients. Blood 1996; 88: 2801–2806
   PubMed Web of Science ®Google Scholar
• Comenzo R L, Gertz M A. Autologous stem cell transplantation for primary systemic amyloidosis. Blood 2002; 99: 4276–4282
   PubMed Web of Science ®Google Scholar
• Gertz M A, Lacy M Q, Dispenzieri A, Ansell S M, Elliott M A, Gastineau D A, Inwards D J, Micallef I N, Porrata L F, Tefferi A, Litzow M R. Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate. Bone Marrow Transplant 2004; 34: 1025–1031
   PubMed Web of Science ®Google Scholar
• Oran B, Malek K, Sanchorawala V, Wright D G, Quillen K, Finn K T, La Valley M, Skinner M, Seldin D C. Predictive factors for hematopoietic engraftment after autologous peripheral blood stem cell transplantation for AL amyloidosis. Bone Marrow Transplant 2005; 35: 567–575
   PubMed Web of Science ®Google Scholar
• Comenzo R L, Michelle D, LeBlanc M, Wally J, Zhang Y, Kica G, Karandish S, Arkin C F, Wright D G, Skinner M, McMannis J. Mobilized CD34+ cells selected as autografts in patients with primary light-chain amyloidosis: rationale and application. Transfusion 1998; 38: 60–69
   PubMed Web of Science ®Google Scholar
• Perz J B, Schonland S O, Hundemer M, Kristen A V, Dengler T J, Zeier M, Linke R P, Ho A D, Goldschmidt H. High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study. Br J Haematol 2004; 127: 543–551
   PubMed Web of Science ®Google Scholar
• Sanchorawala V, Wright D G, Seldin D C, Falk R H, Finn K T, Dember L M, Berk J L, Quillen K, Anderson J J, Comenzo R L, Skinner M. High-dose intravenous melphalan and autologous stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of AL amyloidosis: results of a prospective randomized trial. Bone Marrow Transplant 2004; 33: 381–388
   PubMed Web of Science ®Google Scholar
• Dember L M, Sanchorawala V, Seldin D C, Wright D G, LaValley M, Berk J L, Falk R H, Skinner M. Effect of dose-intensive intravenous melphalan and autologous blood stem-cell transplantation on al amyloidosis-associated renal disease. Ann Intern Med 2001; 134: 746–753
   PubMed Web of Science ®Google Scholar
• Falk R H. Diagnosis and management of the cardiac amyloidoses. Circulation 2005; 112: 2047–2060
   PubMed Web of Science ®Google Scholar
• Choufani E B, Sanchorawala V, Ernst T, Quillen K, Skinner M, Wright D G, Seldin D C. Acquired factor X deficiency in patients with amyloid light-chain amyloidosis: incidence, bleeding manifestations, and response to high-dose chemotherapy. Blood 2001; 97: 1885–1887
   PubMed Web of Science ®Google Scholar
• Oran B, Wright D G, Seldin D C, McAneny D, Skinner M, Sanchorawala V. Spontaneous rupture of the spleen in AL amyloidosis. Am J Hematol 2003; 74: 131–135
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Kyle R A, Lacy M Q, Therneau T M, Larson D R, Plevak M F, Rajkumar S V, Fonseca R, Greipp P R, Witzig T E, Lust J A, Zeldenrust S R, Snow D S, Hayman S R, Litzow M R, Gastineau D A, Tefferi A, Inwards D J, Micallef I N, Ansell S M, Porrata L F, Elliott M A, Gertz M A. Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study. Blood 2004; 103: 3960–3963
   PubMed Web of Science ®Google Scholar
• Gillmore J D, Goodman H J, Lachmann H J, Offer M, Wechalekar A D, Joshi J, Pepys M B, Hawkins P N. Sequential heart and autologous stem cell transplantation for systemic AL amyloidosis. Blood 2006; 1227–1229
   PubMedGoogle Scholar
• Schonland S O, Lokhorst H, Buzyn A, Leblond V, Hegenbart U, Bandini G, Campbell A, Carreras E, Ferrant A, Grommisch L, Jacobs P, Kroger N, La Nasa G, Russell N, Zachee P, Goldschmidt H, Iacobelli S, Niederwieser D, Gahrton G. Allogeneic and syngeneic hematopoietic cell transplantation in patients with amyloid light-chain amyloidosis: a report from the European Group for Blood and Marrow Transplantation. Blood 2006; 107: 2578–2584
   PubMed Web of Science ®Google Scholar
• Kumar K S, Lefkowitch J, Russo M W, Hesdorffer C, Kinkhabwala M, Kapur S, Emond J C, Brown R S, Jr. Successful sequential liver and stem cell transplantation for hepatic failure due to primary AL amyloidosis. Gastroenterology 2002; 122: 2026–2031
   PubMed Web of Science ®Google Scholar
• Nowak G, Westermark P, Wernerson A, Herlenius G, Sletten K, Ericzon B G. Liver transplantation as rescue treatment in a patient with primary AL kappa amyloidosis. Transpl Int 2000; 13: 92–97
   PubMed Web of Science ®Google Scholar
• Seldin D C, Anderson J J, Skinner M, Malek K, Wright D G, Quillen K, Finn K, Oran B, Sanchorawala V. Successful treatment of AL amyloidosis with high-dose melphalan and autologous stem cell transplantation in patients over age 65. Blood 2006; 108: 3945–3947
   PubMed Web of Science ®Google Scholar
• Casserly L F, Fadia A, Sanchorawala V, Seldin D C, Wright D G, Skinner M, Dember L M. High-dose intravenous melphalan with autologous stem cell transplantation in AL amyloidosis-associated end-stage renal disease. Kidney Int 2003; 63: 1051–1057
   PubMed Web of Science ®Google Scholar
• Sanchorawala V, Wright D G, Rosenzweig M, Finn K T, Fennessey S, Zeldis J B, Skinner M, Seldin D C. Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial. Blood 2007; 109: 492–496
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Lacy M Q, Zeldenrust S R, Hayman S R, Kumar S K, Geyer S M, Lust J A, Allred J B, Witzig T E, Rajkumar S V, Greipp P R, Russell S J, Kabat B, Gertz M A. The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood 2007; 109: 465–470
   PubMed Web of Science ®Google Scholar
• Palladini G, Perfetti V, Obici L, Caccialanza R, Semino A, Adami F, Cavallero G, Rustichelli R, Virga G, Merlini G. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood 2004; 103: 2936–2938
   PubMed Web of Science ®Google Scholar
• Palladini G, Perfetti V, Perlini S, Obici L, Lavatelli F, Caccialanza R, Invernizzi R, Comotti B, Merlini G. The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL). Blood 2005; 105: 2949–2951
   PubMed Web of Science ®Google Scholar
• Wechalekar A D, Goodman H J, Lachmann H J, Offer M, Hawkins P N, Gillmore J D. Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. Blood 2007; 109: 457–464
   PubMed Web of Science ®Google Scholar
• Dhodapkar M V, Hussein M A, Rasmussen E, Solomon A, Larson R A, Crowley J J, Barlogie B. Clinical efficacy of high-dose dexamethasone with maintenance dexamethasone/alpha interferon in patients with primary systemic amyloidosis: results of United States Intergroup Trial Southwest Oncology Group (SWOG) S9628. Blood 2004; 104: 3520–3526
   PubMed Web of Science ®Google Scholar
• Gertz M A, Lacy M Q, Dispenzieri A, Hayman S R, Kumar S. Transplantation for amyloidosis. Curr Opin Oncol 2007; 19: 136–141
   PubMed Web of Science ®Google Scholar
• Mollee P N, Wechalekar A D, Pereira D L, Franke N, Reece D, Chen C, Stewart A K. Autologous stem cell transplantation in primary systemic amyloidosis: the impact of selection criteria on outcome. Bone Marrow Transplant 2004; 33: 271–277
   PubMed Web of Science ®Google Scholar
• Schonland S O, Perz J B, Hundemer M, Hegenbart U, Kristen A V, Hund E, Dengler T J, Beimler J, Zeier M, Singer R, Linke R P, Ho A D, Goldschmidt H. Indications for high-dose chemotherapy with autologous stem cell support in patients with systemic amyloid light chain amyloidosis. Transplantation 2005; 80: S160–163
   Web of Science ®Google Scholar
• Chow L Q, Bahlis N, Russell J, Chaudhry A, Morris D, Brown C, Stewart D A. Autologous transplantation for primary systemic AL amyloidosis is feasible outside a major amyloidosis referral centre: the Calgary BMT Program experience. Bone Marrow Transplant 2005; 36: 591–596
   PubMed Web of Science ®Google Scholar
• Moreau P, Leblond V, Bourquelot P, Facon T, Huynh A, Caillot D, Hermine O, Attal M, Hamidou M, Nedellec G, Ferrant A, Audhuy B, Bataille R, Milpied N, Harousseau J L. Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients. Br J Haematol 1998; 101: 766–769
   PubMed Web of Science ®Google Scholar
• Gertz M A, Blood E, Vesole D H, Abonour R, Lazarus H M, Greipp P R. A multicenter phase 2 trial of stem cell transplantation for immunoglobulin light-chain amyloidosis (E4A97): an Eastern Cooperative Oncology Group Study. Bone Marrow Transplant 2004; 34: 149–154
   PubMed Web of Science ®Google Scholar
• Goodman H J, Gillmore J D, Lachmann H J, Wechalekar A D, Bradwell A R, Hawkins P N. Outcome of autologous stem cell transplantation for AL amyloidosis in the UK. Br J Haematol 2006; 134: 417–425
   PubMed Web of Science ®Google Scholar
• Vesole D H, Perez W S, Akasheh M, Boudreau C, Reece D E, Bredeson C N. High-dose therapy and autologous hematopoietic stem cell transplantation for patients with primary systemic amyloidosis: a Center for International Blood and Marrow Transplant Research Study. Mayo Clin Proc 2006; 81: 880–888
   PubMed Web of Science ®Google Scholar